The Alpha Journal — Men’s Health Reporting

Topical dutasteride produces greater improvements in hair density than topical finasteride in head-to-head trials, but finasteride has the larger evidence base, more predictable systemic exposure data, and — as of September 2026 — a cleaner regulatory track record for compounded…

PP405, a first-in-class topical mitochondrial pyruvate carrier inhibitor, produces faster visible regrowth than minoxidil in early trials — but minoxidil has decades of controlled-trial data behind it, and PP405 is not yet commercially available.

Low-dose oral minoxidil (LDOM) and topical minoxidil produce broadly similar hair density gains in men with androgenetic alopecia — but they carry meaningfully different risk profiles, and the right choice depends on your tolerance for systemic side effects, not just efficacy.

Finasteride is the proven standard for male androgenetic alopecia (AGA), backed by decades of randomized trial data — but pyrilutamide (KX-826) is emerging as a credible topical alternative that blocks androgen receptors locally without suppressing systemic DHT.

Dutasteride produces meaningfully greater hair density gains than finasteride — roughly 28 more hairs per target area over 24 weeks in pooled trials — but finasteride remains the only FDA-approved oral option for male pattern hair loss and carries a longer real-world safety…

He Shou Wu (Polygonum multiflorum) hits androgenetic alopecia through at least four distinct biological pathways — and new research is finally explaining why a root used in Chinese medicine for over a millennium keeps showing up in serious hair-loss conversations.

Minoxidil remains the only topical hair-loss treatment with decades of randomized-trial evidence and regulatory approval behind it. Deoxyribose gel is a genuinely interesting challenger — but as of mid-2026, every human trial is still recruiting, and men making treatment…